Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  TESARO Inc    TSRO

TESARO INC (TSRO)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/18/2017 09/19/2017 09/20/2017 09/21/2017 09/22/2017 Date
118.44(c) 118.74(c) 121.62(c) 118.67(c) 119.04(c) Last
731 026 603 303 977 112 346 714 444 133 Volume
+1.09% +0.25% +2.43% -2.43% +0.31% Change
More quotes
Financials ($)
Sales 2017 229 M
EBIT 2017 -452 M
Net income 2017 -463 M
Finance 2017 468 M
Yield 2017 -
Sales 2018 465 M
EBIT 2018 -306 M
Net income 2018 -310 M
Finance 2018 254 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 26,1x
EV / Sales2018 13,3x
Capitalization 6 450 M
More Financials
Company
TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products.It focuses on oncology-based therapeutics and its products include: Rolapitant and Niraparib.The company was founded by Leon Moulder, Jr., Mary Lynne Hedley,... 
Sector
Biotechnology & Medical Research
Calendar
09/28 | 07:00pmPresentation
More about the company
Surperformance© ratings of TESARO Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on TESARO INC
09/20 TESARO : At Attractive Valuation Ahead Of Key Regulatory Decisions
09/19 TESARO : Receives Positive CHMP Opinion for ZEJULA
09/19 TESARO : earns CHMP thumbs-up for Zejula as three-way PARP race heats up
09/19 TESARO : Tesaros Zejula primed for EU approval, battle with AZ
09/19 TESARO : CHMP backs maintenance therapy for Tesaro`s Zejula
09/18 TESARO,INC. (NASDAQ : TSRO) Files An 8-K Other Events
09/18 TESARO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
09/18 TESARO INC : Corporate News Blog - EMA Grants Positive CHMP Opinion to Tesaro’s ..
09/18 FDA Nod For NEOS, One Step Closer To EU Approval Are GSK, TSRO, On Watch Is M..
09/15 TESARO : Receives Positive CHMP Opinion for ZEJULA®
More news
Sector news : Bio Therapeutic Drugs
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Bio Therapeutic Drugs
Latest Tweets
02:41aTESARO, Inc. $TSRO Receives Average Recommendation of “Buy” from Analysts  
09/24Bluestein R H & Co. Has $420,000 Holdings in TESARO, Inc. $TSRO  
09/23Fmr LLC Has $1.08 Billion Position in TESARO, Inc. $TSRO  
09/23$TSRO - Fmr LLC Has $1.08 Billion Position in TESARO, Inc. #TSRO  
09/22James O. Armitage Sells 10,000 Shares of TESARO, Inc. $TSRO Stock  
More tweets
Qtime:24
News from SeekingAlpha
09/19 Tesaro At Attractive Valuation Ahead Of Key Regulatory Decisions
09/18 YOUR DAILY PHARMA SCOOP : ACADIA's Growth Potential, Lexicon's Diabetes Troubles..
09/15 European advisory group backs TESARO's Zejula
09/04 Faison's Weekend Review And Scans
09/01 After Hours Gainers / Losers
Chart TESARO INC
Duration : Period :
TESARO Inc Technical Analysis Chart | TSRO | US8815691071 | 4-Traders
Technical analysis trends TESARO INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 167 $
Spread / Average Target 40%
EPS Revisions
Managers
NameTitle
Leon O. Moulder Chief Executive Officer & Director
Mary Lynne Hedley President, Chief Operating Officer & Director
David M. Mott Chairman
Timothy R. Pearson Chief Financial Officer & Executive Vice President
Martin H. Huber Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
TESARO INC-11.76%6 450
AMGEN27.65%135 544
CELGENE CORPORATION24.22%112 572
GILEAD SCIENCES15.37%108 744
REGENERON PHARMACEUTICALS18.08%46 367
VERTEX PHARMACEUTICALS106.41%38 136